| 28.38 0.25 (0.89%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.25  |
1-year : | 38.83 |
| Resists | First : | 28.46 |
Second : | 33.25 |
| Pivot price | 27.04 |
|||
| Supports | First : | 26.03 |
Second : | 24.53 |
| MAs | MA(5) : | 28.02 |
MA(20) : | 26.55 |
| MA(100) : | 28.33  |
MA(250) : | 30.84 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 94.6 |
D(3) : | 94.8 |
| RSI | RSI(14): 68.1 |
|||
| 52-week | High : | 41.58 | Low : | 24.53 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GMAB ] has closed below upper band by 13.6%. Bollinger Bands are 29.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.51 - 28.61 | 28.61 - 28.7 |
| Low: | 27.85 - 27.99 | 27.99 - 28.09 |
| Close: | 28.18 - 28.39 | 28.39 - 28.55 |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Thu, 25 Jul 2024
GMAB vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance Australia
Wed, 24 Jul 2024
Genmab (CPH:GMAB) jumps 4.5% this week, though earnings growth is still tracking behind five-year shareholder returns - Simply Wall St
Tue, 23 Jul 2024
1,453 Shares in Genmab A/S (NASDAQ:GMAB) Bought by Allspring Global Investments Holdings LLC - Defense World
Tue, 23 Jul 2024
Genmab A/S (NASDAQ:GMAB) Receives Average Recommendation of “Hold” from Analysts - Defense World
Fri, 19 Jul 2024
Q2 2024 EPS Estimates for Genmab A/S Increased by Analyst (NASDAQ:GMAB) - American Banking and Market News
Fri, 19 Jul 2024
SG Americas Securities LLC Grows Holdings in Genmab A/S (NASDAQ:GMAB) - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 635 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 7.5 (%) |
| Shares Short | 2,300 (K) |
| Shares Short P.Month | 2,870 (K) |
| EPS | 1.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 498.86 |
| Profit Margin | 30.7 % |
| Operating Margin | 19.3 % |
| Return on Assets (ttm) | 10.6 % |
| Return on Equity (ttm) | 18.3 % |
| Qtrly Rev. Growth | 45.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 28.01 |
| EBITDA (p.s.) | 9.37 |
| Qtrly Earnings Growth | 488.2 % |
| Operating Cash Flow | 5,660 (M) |
| Levered Free Cash Flow | 3,830 (M) |
| PE Ratio | 23.26 |
| PEG Ratio | 1.8 |
| Price to Book value | 0.05 |
| Price to Sales | 1.01 |
| Price to Cash Flow | 3.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|